Skip to main content

Advertisement

Log in

Steroid preservation: the rationale for continued prescribing

  • Editorial Commentary
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Tailored immunosuppression according to risk stratification for optimal outcome for both immunological and non-immunological risk factors should be the ultimate objective for every child in whom renal transplantation is planned. Renal allograft survival is dependent on the appropriate use of immunosuppressive therapy to prevent acute rejection and chronic allograft nephropathy. Unfortunately, all immunosuppressive therapies, including corticosteroids, have unwanted side effects, including infections, malignancy, nephrotoxicity, hypertension, hyperlipidaemia and diabetes mellitus. However, the most worrying side effects of corticosteroids for children, adolescents and their parents are growth retardation and the cosmetic effects. Consequently, achieving immunosuppressive regimens without corticosteroids would be preferable. The major concern for paediatric nephrologists in the 21st century is no longer acute rejection, as the incidence appears to be decreasing, but infection, particularly EBV and the development of post-transplant lymphoproliferative disease (PTLD). With modern immunosuppressive agents in transplantation, rejection is being traded for infection. The long-term outcome data of PTLD with steroid-free and monoclonal antibody protocols is as yet unknown.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Karin M (1998) New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 93:487–490

    PubMed  Google Scholar 

  2. Birkeland SA, Larsen KE, Rohr N (1998) Pediatric renal transplantation without steroids. Pediatr Nephrol 12:87–92

    PubMed  Google Scholar 

  3. Chakrabarti P, Wong HY, Scantlebury VP, Jordan ML, Vivas C, Ellis D, Lombardozzi-Lane S, Hakala TR, Fung JJ, Simmons RL, Starzl TE, Shapiro R (2000) Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 70:760–764

    PubMed  Google Scholar 

  4. Roberti I, Reisman L, Lieberman KV, Burrows L (1994) Risk of steroid withdrawal in pediatric renal allograft recipients (a 5-year follow-up). Clin Transplant 8:405–408

    PubMed  Google Scholar 

  5. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report (2005) http://spitfire.emmes.com/study/ped/resources/annlrept2005.pdf, 1–266 Accessed online on 16 October 2005. Ref Type: Generic

    Google Scholar 

  6. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC (2005) Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331:810

    PubMed  Google Scholar 

  7. Hymes LC, Warshaw BL (2005) Sirolimus in pediatric patients: results in the first 6 months post-renal transplant. Pediatr Transplant 9:520–522

    PubMed  Google Scholar 

  8. Benfield MR, McDonald RA, Bartosh S, Ho PL, Harmon W (2003) Changing trends in pediatric transplantation: 2001 Annual Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 7:321–335

    PubMed  Google Scholar 

  9. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE (2001) Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 71:1065–1068

    PubMed  Google Scholar 

  10. Funch DP, Brady J, Ko HH, Dreyer NA, Walker AM (2002) Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients. Recent Results Cancer Res 159:81–88

    PubMed  Google Scholar 

  11. Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med 353:1711–1723

    PubMed  Google Scholar 

  12. Ortiz PA, Garvin JL (2003) Cardiovascular and renal control in NOS-deficient mouse models. Am J Physiol Regul Integr Comp Physiol 284:R628–R638

    PubMed  Google Scholar 

  13. Pape L, Ehrich JH, Zivicnjak M, Offner G (2005) Growth in children after kidney transplantation with living related donor graft or cadaveric graft. Lancet 366:151–153

    PubMed  Google Scholar 

  14. Fine RN, Stablein D (2005) Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry. Pediatr Nephrol 20:404–408

    PubMed  Google Scholar 

  15. Nissel R, Brazda I, Feneberg R, Wigger M, Greiner C, Querfeld U, Haffner D (2004) Effect of renal transplantation in childhood on longitudinal growth and adult height. Kidney Int 66:792–800

    PubMed  Google Scholar 

  16. Sarwal M (2005) Steroid elimination is coming of age. Pediatr Nephrol 21:2–4 DOI:10.1007/s00467-005-1042-2

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stephen D. Marks.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marks, S.D., Trompeter, R.S. Steroid preservation: the rationale for continued prescribing. Pediatr Nephrol 21, 305–307 (2006). https://doi.org/10.1007/s00467-005-2155-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-005-2155-7

Keywords

Navigation